Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum
Ganoderic acid, from Ganoderma lucidum, at 8 µg/ml inhibited replication of hepatitis B virus (HBV) in HepG2215 cells over 8 days. Production of HBV surface antigen and HBV e antigen were 20 and 44% of controls without ganoderic acid. Male KM mice were significantly protected from liver injury, induced with carbon tetrachloride, by treatment with ganoderic acid at 10 mg and 30 mg/kg·d (by intravenous injection) 7 days. Ganoderic acid at the same dosage also significantly protected the mice from liver injury induced by M. bovis BCG plus lipopolysaccharide (from Escherichia coli 0127:B8).
KeywordsGanoderic acid Ganoderma lucidum Hepatitis Hepatoprotection Virus
Unable to display preview. Download preview PDF.
- Hoder M, Wilkinson JH (1980) Enzymes. In: Brown SS, Mitchel FL, Young SD (eds) Chemical diagnosis of disease, 2nd edn. Biomed Press, New YorkGoogle Scholar
- Recknagel RO (1967) Carbon tetrachloride hepatotoxicity. Pharmacol Res 19:145–208Google Scholar
- Sinha KP, Saran A (1972) Serum transaminase levels during the course of administration of carbon tetrachloride to rabbits. Ind J Med Res 60:1378–1381Google Scholar
- Tsujikura Y, Higuchi T, Miyamoto Y, Sato S (1992) Manufacture of ganoderic acid by fermentation of Ganoderma lucidum. Japanese Patent. JP04304890Google Scholar